Mount Sinai Health System | Strategic Alliance Partners

Sundar Jagannath, MBBS, highlights pharmacists’ expanding role in managing linvoseltamab’s immunologic profile, supporting adverse event response, and advancing multiple myeloma care.

Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.

Sundar Jagannath, MD, MBBS, explains how linvoseltamab showed strong efficacy and tolerability in the LINKER-MM1 trial, making it an appealing option for older patients with relapsed or refractory multiple myeloma (MM).

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

Anna Sophie Mueller, MD discusses how imaging could advance risk identification in cardiovascular care.

Pharmacy Times® is pleased to announce that four new organizations have joined its Strategic Alliance Partnership program.

The COVID-19 pandemic has led to significant innovation, which presents a unique opportunity for pharmacists to advance pharmacy practice by serving as the integral drug monitoring experts of the health care team.

Could giving patients money help improve their adherence? Mount Sinai is currently piloting a new platform to find out.